Scalper1 News
Shares of Juno Therapeutics (JUNO) soared as high as 16% in trading Tuesday on reports that AstraZeneca’s (AZN) CEO said he saw Juno as a potential acquisition target. Bloomberg came out with the full story on its interview with AstraZeneca CEO Pascal Soriot in the early afternoon, but Juno’s stock first jumped in midmorning when Bloomberg terminal subscribers got a few tidbits that were then passed along through StreetInsider and other media Scalper1 News
Scalper1 News